Objective: The aims of this report are to quantify and compare competing risks associated with the use of non-prescription analgesics (daily doses of acetaminophen ≤ 4000 mg, aspirin ≤ 4000 mg, ibuprofen ≤ 1200 mg, naproxen ≤ 660 mg and ketoprofen ≤ 75 mg) and identify research needs.
Methods: Literature was searched and organized by medication, adverse effect and direction of effect. Causality was determined using structured consensus, using IOM and GRADE nomenclature. Magnitude of risk data were extracted from primary sources. Structured consensus were used to construct a list of research priorities.
Results: The available data favor acceptance of a causal relationship between each of the five analgesics studied and at least one specific form of harm. Dosing in excess of the non-prescription limits is associated with increased risk. Existing data do not support precise estimates of population or individual patient attributable risks for most analgesic and organ system combinations, and as a result competing risks cannot be adequately assessed. The highest priority research needs included understanding 'real world' dosing and how co-morbidities and prodromal symptoms modify exposure.
Conclusions: Although generally safe, all non-prescription analgesics are associated with some harm, particularly when recommended dosing limits are exceeded. Research to quantify the competing risks of different analgesic strategies is urgently needed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1517/14740338.2012.629782 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Patterns and social factors associated with non-prescription use of Tramadol: a cross-sectional study among youth in urban informal settlements in Ghana.
J Health Popul Nutr
November 2024
African Population and Health Research Center, Nairobi, Kenya.
Background: Non-prescription use of Tramadol is increasingly becoming common among vulnerable populations. This study examines the factors associated with non-prescription use of Tramadol among youth in urban informal settlements in the Asokore Mampong Municipality, Ghana.
Methods: Cross-sectional data from Tramadol users aged 15 to 35 years living in urban informal settlements were analyzed.
Use of over-the-counter supplements, sleep aids and analgesic medicines in rheumatology: results of a cross-sectional survey.
Rheumatol Adv Pract
October 2024
Centre for Epidemiology Versus Arthritis, Centre for Musculoskeletal Research, University of Manchester, Manchester, UK.
Objectives: Pain, fatigue and sleep disturbances are common symptoms in patients with rheumatic and musculoskeletal diseases (RMDs) that may prompt the use of over-the-counter (OTC) supplements, sleep aids and analgesics as self-management strategies. This study evaluated the prevalence of OTC supplements, sleep aids and pain relievers and the financial burden associated with their use in rheumatology.
Methods: A web-based survey developed with patients was administered in rheumatology clinics in an English hospital.
Chronic pain and use of painkillers, healthcare services and long-term impairment among Syrian refugees: a cross-sectional study.
BMC Public Health
October 2024
Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway.
Background: The global increase in forcibly displaced populations highlights the importance of understanding their health needs. Chronic pain is prevalent among refugees, poses significant personal and public health challenges, and complicates their integration into new home countries. Understanding refugees' pain post-migration and how it is being managed is crucial for ensuring adequate and timely interventions and fostering health equity.
View Article and Find Full Text PDFPRECISE trial (Pain RElief Combination Intervention StratEgies): protocol for the clinical trial of a pregabalin-melatonin combination for fibromyalgia.
BMJ Open
June 2024
Clinical Neurological Sciences and Oncology, Western University, London, Ontario, Canada.
Article Synopsis
- Fibromyalgia causes chronic pain and sleep disturbances, and current treatment options only significantly help 30-60% of patients; therefore, a study will examine the effectiveness of combining melatonin and pregabalin in treating this condition.
- The trial will involve 54 adults diagnosed with fibromyalgia, assessing pain levels and other health outcomes over 6 weeks while comparing the combination treatment to the individual medications.
- Ethical approval for the trial has been secured, and it is registered for transparency and adherence to research standards.
Multi-microdialysis analytical system to monitor acetaminophen and its pharmacokinetic interaction with A. bidentata in rat blood, forelimb extensor muscle, brain striatum, and the knee joint cavity.
J Pharm Biomed Anal
September 2024
Institute of Traditional Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei 112, Taiwan; Graduate Institute of Acupuncture Science, China Medical University, Taichung 404, Taiwan; Graduate Institute of Law and Interdisciplinary Studies, College of Law, National Chengchi University, Taipei 116, Taiwan; School of Pharmacy, Kaohsiung Medical University, Kaohsiung 807, Taiwan. Electronic address:
Acetaminophen (APAP), or paracetamol, is one of the most widespread and commonly used non-prescription pain medication in the world, and is effective at managing wide range of pain, including headache, muscle ache, and minor arthritic pain. While the pharmacokinetics of APAP is generally understood, there is a lack of data for its transfer ratio especially into the knee. A novel multi-microdialysis model was developed to simultaneously sample from blood, forelimb extensor muscle, brain striatum, and the knee joint cavity in the same experimental subject to investigate the potential interaction between APAP and Achyranthes bidentata Blume (A.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!